Physician knowledge, use, and perceptions of genetic biomarker testing for the management of patients with newly diagnosed advanced ovarian cancer: an international physician survey.

IF 3 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2025-02-01 Epub Date: 2025-01-15 DOI:10.1080/14796694.2025.2449782

Susana Banerjee, Ramez N Eskander, Tom Bailey, Will Ambler, Stephanie Volpe, Ozan Özgören, Jacek P Grabowski, Giorgio Valabrega

{"title":"Physician knowledge, use, and perceptions of genetic biomarker testing for the management of patients with newly diagnosed advanced ovarian cancer: an international physician survey.","authors":"Susana Banerjee, Ramez N Eskander, Tom Bailey, Will Ambler, Stephanie Volpe, Ozan Özgören, Jacek P Grabowski, Giorgio Valabrega","doi":"10.1080/14796694.2025.2449782","DOIUrl":null,"url":null,"abstract":"Aims: To explore physician-reported knowledge, use, and perceptions of genetic testing for advanced ovarian cancer management.Materials & methods: Gynecology/oncology specialists (n = 390) in the US, Europe, Canada, Japan, and Australia completed an online survey spanning March 2021 to April 2022.Results: Physician-reported breast cancer gene mutation (BRCAm) testing rates increased over the 2 years before the survey; most patients underwent testing in the preceding 6 months. Homologous recombination deficiency (HRD) genomic instability testing rates and physicians' confidence interpreting results remained relatively low. Genetic testing was driven by the associated treatment implications of the findings. Poor performance status, inadequate tissue, and patients' willingness to undergo testing were reported barriers to testing.Conclusions: Findings indicate that there is a need to improve both access to and information about HRD testing.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"437-445"},"PeriodicalIF":3.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2449782","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/15 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: To explore physician-reported knowledge, use, and perceptions of genetic testing for advanced ovarian cancer management.

Materials & methods: Gynecology/oncology specialists (n = 390) in the US, Europe, Canada, Japan, and Australia completed an online survey spanning March 2021 to April 2022.

Results: Physician-reported breast cancer gene mutation (BRCAm) testing rates increased over the 2 years before the survey; most patients underwent testing in the preceding 6 months. Homologous recombination deficiency (HRD) genomic instability testing rates and physicians' confidence interpreting results remained relatively low. Genetic testing was driven by the associated treatment implications of the findings. Poor performance status, inadequate tissue, and patients' willingness to undergo testing were reported barriers to testing.

Conclusions: Findings indicate that there is a need to improve both access to and information about HRD testing.

查看原文本刊更多论文

医生的知识，使用和认识的遗传生物标志物检测管理的新诊断晚期卵巢癌患者：一项国际医师调查。

目的：探讨医生报告的晚期卵巢癌管理中基因检测的知识、使用和认知。材料与方法：美国、欧洲、加拿大、日本和澳大利亚的妇科/肿瘤学专家（n = 390）在2021年3月至2022年4月期间完成了一项在线调查。结果：医生报告的乳腺癌基因突变（BRCAm）检测率在调查前2年有所增加；大多数患者在前6个月接受了检测。同源重组缺陷（HRD）基因组不稳定性检测率和医生解释结果的信心仍然相对较低。基因检测是由研究结果的相关治疗意义驱动的。据报道，表现不佳、组织不足和患者接受检测的意愿是检测的障碍。结论：研究结果表明，有必要改善HRD检测的可及性和信息。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.